Bloom Energy Stock Faces Key Risks as Growth Fuels S&P 500 Index Inclusion
Bloom Energy jumped to a crucial resistance level as its revenue growth fueled its upcoming inclusion to the S&P 500 Index.
Stocks · News reference
This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
https://www.spglobal.com/spdji/en//documents/indexnews/announcements/20260904-1484999/1484999_shuffle5461-sept2026.pdf
Why Is Bloom Energy Stock Surging on Friday?
Bloom Energy Corp. (NYSE: TEL) stock rises Friday amid speculation over S&P 500 index inclusion and lower U.S. Treasury yields.
I'm Calling It: Bloom Energy's Revenue Guidance Will Keep Surprising Wall Street Through Year-End
Bloom Energy, a fuel cell manufacturer, has raised its full-year revenue guidance to $3.9-$4.2 billion (up from $3.4-$3.8 billion) driven by surging demand for AI data center power solutions. With Q2 revenue reaching $1.0 billion and expanding partnerships with Oracle and MiTAC, the company is well-positioned to continue delivering positive surprises through year-end as AI infrastructure investments remain robust.
Kymera Therapeutics Says Enrollment Completed In Phase 2b BROADEN2 Trial Of KT-621 In Atopic Dermatitis, With Topline Data Expected By Year-End 2026; Phase 3 Trials Planned To Initiate By Mid-2027
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170
Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $170.